Vattenfall AB Outlook Revised To Stable On Growing Regulatory And Political Pressure Sep 06

  • ID: 2027120
  • September 2006
  • Standard & Poors
1 of 3

STOCKHOLM (Standard & Poor's) Sept. 6, 2006--Standard & Poor's Ratings Services said today it revised its outlook on Sweden-based integrated power utility Vattenfall AB to stable from positive. At the same time, the 'A-' long-term and 'A-2' short-term corporate credit ratings on Vattenfall were affirmed. The outlook revision reflects the increasing regulatory and political pressure in Vattenfall's main markets of Sweden and Germany. The company is also significantly stepping up its capital expenditure program over the medium term. At June 30, 2006, Vattenfall had Swedish krona (Skr) 69 billion ($9.5 billion) in interest-bearing debt outstanding (including Skr9.1 billion in hybrid capital notes as debt). "The prospect of continued improved credit quality is tempered by increasing regulatory and political pressure in...

Companies mentioned in this report are:
- Vattenfall AB

Action: Affirmed
Action: Outlook: Stable

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Vattenfall AB

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.